Abstract
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Clinically, it is characterized by progressive cognitive impairment and the emergence of neuropsychiatric disturbances. In recent years, many drug candidates aimed at disease modification have advanced into large, randomized controlled trials, but none have demonstrated efficacy in slowing down the relentless progression of AD. While the exact cause of AD is still being fervently investigated, the field is moving toward earlier identification and treatment of the disease, as it is believed this may be the main reason for so many clinical trial failures.
There are currently four main mechanisms of action that are being actively developed in AD therapeutics: Drugs aimed at reducing Aβ production, notably secretase inhibitors; Drugs aimed at reducing Aβ plaque burden via inhibition of aggregatio or disruption of aggregates; Drugs aimed at promoting Aβ clearance via active or passive immunotherapy; and Drugs aimed at preventing tau protein phosphorylation.
In this review, recent findings from clinical and preclinical studies in each of these categories will be discussed, as well as a category entitled ‘ other therapies,’ that includes treatments that do not fit under a single mechanism of action, but represent rational interventions for the underlying pathology of Alzheimer’s disease.
Keywords: Alzheimer’s disease, Mild Cognitive Impairment, Prodromal Alzheimer’s disease, Anti-amyloid treatment.
Reviews on Recent Clinical Trials
Title:Update on Alzheimer’s Disease Therapeutics
Volume: 8 Issue: 2
Author(s): Michael S. Rafii
Affiliation:
Keywords: Alzheimer’s disease, Mild Cognitive Impairment, Prodromal Alzheimer’s disease, Anti-amyloid treatment.
Abstract: Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Clinically, it is characterized by progressive cognitive impairment and the emergence of neuropsychiatric disturbances. In recent years, many drug candidates aimed at disease modification have advanced into large, randomized controlled trials, but none have demonstrated efficacy in slowing down the relentless progression of AD. While the exact cause of AD is still being fervently investigated, the field is moving toward earlier identification and treatment of the disease, as it is believed this may be the main reason for so many clinical trial failures.
There are currently four main mechanisms of action that are being actively developed in AD therapeutics: Drugs aimed at reducing Aβ production, notably secretase inhibitors; Drugs aimed at reducing Aβ plaque burden via inhibition of aggregatio or disruption of aggregates; Drugs aimed at promoting Aβ clearance via active or passive immunotherapy; and Drugs aimed at preventing tau protein phosphorylation.
In this review, recent findings from clinical and preclinical studies in each of these categories will be discussed, as well as a category entitled ‘ other therapies,’ that includes treatments that do not fit under a single mechanism of action, but represent rational interventions for the underlying pathology of Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Rafii S. Michael, Update on Alzheimer’s Disease Therapeutics, Reviews on Recent Clinical Trials 2013; 8 (2) . https://dx.doi.org/10.2174/15748871113089990045
DOI https://dx.doi.org/10.2174/15748871113089990045 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transcription Factor NF-κB Inhibitors as Single Therapeutic Agents or in Combination with Classical Chemotherapeutic Agents for the Treatment of Hematologic Malignancies
Current Molecular Pharmacology Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms
Combinatorial Chemistry & High Throughput Screening NK Cell Function in HIV-1 Infection
Current HIV Research Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective
CNS & Neurological Disorders - Drug Targets A Pilot Study Evaluating Combinatorial and Simultaneous Delivery of Polyethylenimine-Plasmid DNA Complexes Encoding for VEGF and PDGF for Bone Regeneration in Calvarial Bone Defects
Current Pharmaceutical Biotechnology MicroRNA and HER2-overexpressing Cancer
MicroRNA Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition
Current Pharmaceutical Design Lysine Methyltransferases Signaling: Histones are Just the Tip of the Iceberg
Current Protein & Peptide Science Functions of S100 Proteins
Current Molecular Medicine The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design The Fractal Viewpoint of Tumors and Nanoparticles
Current Medicinal Chemistry Antimitotic Chalcones and Related Compounds as Inhibitors of Tubulin Assembly
Anti-Cancer Agents in Medicinal Chemistry Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment
Current Neuropharmacology In Vitro Antitumoral Activity of Palladium(II) and Platinum(II) Complexes with O,O'-Dialkyl Esters of Ethylene-bis(S)-Leucine
Letters in Drug Design & Discovery Applications of Mannich Reaction in Total Syntheses of Natural Products
Current Organic Chemistry Synthesis and In Vitro Anticancer Activity of Novel 2-((3-thioureido)carbonyl) phenyl Acetate Derivatives
Letters in Drug Design & Discovery Nucleoside Phosphorylases
Current Organic Chemistry